Matthew Thompson's most recent trade in Vivos Therapeutics Inc was a trade of 4,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vivos Therapeutics Inc | Matthew Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,000 | 7,067 | - | - | Stock Option (Right to Buy) | |
| Vivos Therapeutics Inc | Matthew Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2022 | 30,000 | 76,667 | - | - | Stock Option (Right to Buy) | |
| Vivos Therapeutics Inc | Matthew Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2021 | 30,000 | 46,667 | - | - | Stock Option (Right to Buy) | |
| NCR Corp. | Matthew Thompson | Director | Grant, award, or other acquisition of securities at price $ 40.19 per share. | 20 Apr 2021 | 5,599 | 36,886 (0%) | 0% | 40.2 | 225,024 | Common Stock |